Pfizer COVID-19 clinical trials: antiviral PF-07321332 and Pfizer antiviral PF-07304814
… Pfizer researching oral and IV COVID-19 antiviral therapies PF-07321332 and PF-07304814

Pfizer Launches Phase 1 Clinical Trial For Oral COVID-19 Antiviral Drug

John G. Baresky

Global pharmaceutical giant Pfizer (NYSE: PFE) is evaluating antiviral product pipeline candidates to treat COVID-19 via oral administration as well as IV therapy.

The promising new oral drug candidate, designated as PF-07321332, is being evaluated in a Phase 1, randomized, double-blind, sponsor-open, placebo-controlled, single- and multiple-dose escalation study to evaluate its safety, tolerability, and pharmacokinetics in healthy adult patients.

The experimental compound is classified as a protease inhibitor. Protease inhibitors prevent viruses from multiplying by selectively binding to viral proteases and blocking the proteolytic cleavage of protein precursors that are required for viruses to replicate.

Protease inhibitors are presently used as FDA-approved therapies to treat HIV/AIDS and Hepatitis C or “Hep-C”. They are being further explored for use to treat other viral pathogens such as malaria.

Pfizer is also hard at work on developing another protease inhibitor, PF-07304814, that is administered by IV infusion. PF-07304814 is engaged in a phase 1b clinical trial in patients diagnosed with Covid-19. It is a 2-part study exclusively focused on hospitalized COVID-19 patients.

The first portion of the study is to assess safety, tolerability, PK and clinical performance levels of escalating doses of PF-07304814 administered as 24-hour IV infusion. The second part of the study is to determine the safety, tolerability, PK and clinical performance levels of escalating doses of PF- 07304814 administered by 120-hour infusion.

Pfizer has been at the forefront of the COVID-19 pandemic from the start. It is the first company, along with its partner BioNTech SE (NASDAQ: BNTX), to develop a COVID-19 vaccine approved by U.S. Food and Drug Administration (FDA).

Both PF-07321332 and PF-07304814 are extraordinarily valuable assets for Pfizer and the medical community. An oral COVID-19 antiviral agent may help prevent patients from being hospitalized. An additional IV administered COVID-19 antiviral agent helps widen the selection of products clinicians can choose from to optimize clinical outcomes based on individual patient factors.

Pfizer is a global leader in developing vaccines and antiviral therapies to prevent or treat COVID-19 infection
Pfizer is a global leader in developing vaccines and antiviral therapies to prevent or treat COVID-19 infection

In the United States, over 2,900 medical professionals have died as a result of COVID-19 infection and more than 540,000 persons overall have had their lives taken by the coronavirus across the nation.

COVID-19 is far from being neutralized as a healthcare danger as outbreaks continue to occur within the United States and throughout the world. The medical and research community continues to learn about this persistent and deadly pathogen; its variants pose further clinical challenges and lethal threats worldwide.

Not all patients respond well to existing treatments and the anticipated, natural mutation of the coronavirus could require a new array of tests and medications to overcome them. The progress in the development and manufacturing of a variety of pharmaceutical products to treat COVID-19 is encouraging and significantly important.

Learn more about what has been accomplished and what is underway from this helpful list of articles featuring strategic insights on enterprises developing and manufacturing COVID-19 antiviral therapy, diagnostics and vaccines:

COVID-19 Antivirals:

COVID-19 Diagnostics:

COVID-19 Vaccines:

Moving forward, these and other companies have enormous opportunities to achieve clinical and commercial growth through the development of future COVID-19 therapies. Their success is highly anticipated by consumers, patients, medical professionals, healthcare provider organizations, payers, governments and investors.

Thank you for reading this story

Read my other articles about medical and healthcare business trends, content marketing and digital strategy, brand and product management, consumer wellness, managed care, and market access strategy. Contact me today for your healthcare content writing and content strategy needs for medical, business, academic, patient, and consumer healthcare audiences.

I have over 20 years of experience in the healthcare industry producing valuable healthcare content for audiences and customers spanning physicians, nurses, pharmacists plus pharmaceutical companies, medical technology manufacturers, healthcare provider organizations, managed care, investors, consumers, and other stakeholders.

Visit and connect…

LinkedIn

Twitter

Bare Sky Marketing Blog

Bare Sky Marketing Examples

Google My Business

As a healthcare content writer, my work aligns with an organization’s voice, brand, SEO elements, marketplace and objectives. It establishes trust in their company and recognized value in its products and services that generates revenue.

This experience was earned through working at Walgreens, Pfizer, AbelsonTaylor, TAP (Takeda Abbott Partnership), Hospira Worldwide and Boston Software Systems. ​

To a large degree, my professional interests emulate my family which includes doctors, nurses, physician assistants and other clinicians plus those that are working in healthcare administration and commercial enterprises.

Bare Sky Marketing LinkedIn Business Profile

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store